'Tumor immunology meets oncology (TIMO) VII' from 15th to 16th of April 2011 in Halle/Saale, Germany.
- Published in:
- 2011
- By:
- Publication type:
- Report
Works matching IS 03407004 AND DT 2011 AND VI 60 AND IP 11
Results: 12
1
2
Priming with very low-affinity peptide ligands gives rise to CD8 T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF)β-mediated suppression.
- Published in:
- Cancer Immunology, Immunotherapy, 2011, v. 60, n. 11, p. 1543, doi. 10.1007/s00262-011-1043-1
- By:
- Publication type:
- Article
3
Vaccination of patients with cutaneous melanoma with telomerase-specific peptides.
- Published in:
- Cancer Immunology, Immunotherapy, 2011, v. 60, n. 11, p. 1553, doi. 10.1007/s00262-011-1061-z
- By:
- Publication type:
- Article
4
Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide.
- Published in:
- Cancer Immunology, Immunotherapy, 2011, v. 60, n. 11, p. 1565, doi. 10.1007/s00262-011-1051-1
- By:
- Publication type:
- Article
5
Prostaglandin E (PGE) suppresses natural killer cell function primarily through the PGE receptor EP4.
- Published in:
- Cancer Immunology, Immunotherapy, 2011, v. 60, n. 11, p. 1577, doi. 10.1007/s00262-011-1064-9
- By:
- Publication type:
- Article
6
Increased prevalence of regulatory T cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin.
- Published in:
- Cancer Immunology, Immunotherapy, 2011, v. 60, n. 11, p. 1587, doi. 10.1007/s00262-011-1059-6
- By:
- Publication type:
- Article
7
Vaccination with CD133 melanoma induces specific Th17 and Th1 cell-mediated antitumor reactivity against parental tumor.
- Published in:
- Cancer Immunology, Immunotherapy, 2011, v. 60, n. 11, p. 1597, doi. 10.1007/s00262-011-1063-x
- By:
- Publication type:
- Article
8
Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activation.
- Published in:
- Cancer Immunology, Immunotherapy, 2011, v. 60, n. 11, p. 1609, doi. 10.1007/s00262-011-1058-7
- By:
- Publication type:
- Article
9
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
- Published in:
- Cancer Immunology, Immunotherapy, 2011, v. 60, n. 11, p. 1625, doi. 10.1007/s00262-011-1041-3
- By:
- Publication type:
- Article
10
Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer.
- Published in:
- Cancer Immunology, Immunotherapy, 2011, v. 60, n. 11, p. 1639, doi. 10.1007/s00262-011-1086-3
- By:
- Publication type:
- Article
11
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
- Published in:
- Cancer Immunology, Immunotherapy, 2011, v. 60, n. 11, p. 1509, doi. 10.1007/s00262-011-1103-6
- By:
- Publication type:
- Article
12
Dual biological effects of the cytokines interleukin-10 and interferon-γ.
- Published in:
- Cancer Immunology, Immunotherapy, 2011, v. 60, n. 11, p. 1529, doi. 10.1007/s00262-011-1104-5
- By:
- Publication type:
- Article